In light of the failure of Right to Try bill in The House, some background here: "Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits" https://t.co/OZeGE9GXQV by @LiaTsimberidou et al from @MDAndersonNews#rightotry#openaccess
Cefiderocol, a cephalosprin which targets siderophore uptake, suggested to have the potential to become first-line therapy for our most aggressive and lethal multidrug-resistant Gram-negative pathogens https://t.co/Zbhs827jL0
Paper on discontinued #Alzheimer's drugs is particularly relevant today: "Why are they failing? Is the treatment of symptomatic dementia too late? Are the therapeutic targets incorrect? Are the clinical methodologies imprecise, misleading, or inaccurate?" https://t.co/d1OgWgUXwZ https://t.co/aO17x0rxoI
Great to see @EnriqueSoto8 and @smlichtman_md's editorial "Considerations for clinical trial design in older adults with cancer" being featured in the #HemeAging session at last month's American Society of Hematology 2017 Annual Meeting #ASH17#GeriOnc https://t.co/6DEDl4PD7U
Endoglin and ALK1 as therapeutic targets for hereditary hemorrhagic telangiectasia written by Ruiz-Llorente et al (@CIBERER) is Open Access and available here at Expert Opinion on Therapeutic Targets: https://t.co/TO34zvkGu2
Interesting perspective on an emerging field - Investigational PD-1 inhibitors for advanced non-small lung cancer, new players in a shifting paradigm. Free to read editorial by Ghanem et al from @NorthwellHealth, available here: https://t.co/YC8bqZvRuc
Editorial by @EnriqueSoto8 & @smlichtman_md - "Considerations for clinical trial design in older adults with cancer" is free to view online! https://t.co/6np3YbK2TZ
@TheScientistLLC The MERS-CoV spike protein review that is referred to in this article is free to access for April! https://t.co/3tk5EmVjiq https://t.co/J0mzj45lwM